Tildrakizumab
| Monoclonal antibody | |
|---|---|
| Source | Humanized (from mouse) |
| Target | IL23 |
| Clinical data | |
| Identifiers | |
| 1326244-10-3 | |
| None | |
| Chemical data | |
| Formula | C6426H9918N1698O2000S46 |
| 144.4 kDa | |
Tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[1]
Tildrakizumab was designed to block interleukin-23, a cytokine that plays an important role in managing the immune system and autoimmune disease. Originally developed by Schering-Plough, this drug is now part of Merck's clinical program, following that company's acquisition of Schering-Plough.
As of March 2014, the drug was in phase III clinical trials for plaque psoriasis. The two trials will enroll a total of nearly 2000 patients, and preliminary results are expected in June, 2015. [2][3]
See also
- Ustekinumab, a monoclonal antibody targeting both IL-12 and IL-23 and used to treat plaque psoriasis, launched in the United States under the brand name Stelara
- Guselkumab, another experimental, IL-23-specific monoclonal antibody
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Tildrakizumab, American Medical Association.
- ↑ http://clinicaltrials.gov/ct2/show/NCT01729754?term=SCH-900222&phase=2&fund=2&rank=1
- ↑ http://clinicaltrials.gov/ct2/show/NCT01722331?term=SCH-900222&phase=2&fund=2&rank=2